MCRB - Seres Therapeutics Inc Stock Price, Fair Value and News

0.920.00 (0.00%)Market Closed

Market Summary

0.920.00

Market Closed

0.00%

MCRB Stock Price

View Fullscreen

MCRB RSI Chart

MCRB Valuation

Market Cap

139.3M

Price/Earnings (Trailing)

-1.69

Price/Sales (Trailing)

1.1

Price/Free Cashflow

-1.74

MCRB Price/Sales (Trailing)

MCRB Profitability

Return on Equity

138.41%

Return on Assets

-24.23%

Free Cashflow Yield

-57.4%

MCRB Fundamentals

MCRB Revenue

Revenue (TTM)

126.3M

Rev. Growth (Yr)

-93.44%

Rev. Growth (Qtr)

-79.35%

MCRB Earnings

Earnings (TTM)

-82.7M

Earnings Growth (Yr)

43.61%

Earnings Growth (Qtr)

2.7%

Breaking Down MCRB Revenue

Last 7 days

-9.8%

Last 30 days

46.0%

Last 90 days

-12.4%

Trailing 12 Months

-80.9%

How does MCRB drawdown profile look like?

MCRB Financial Health

Current Ratio

1.68

MCRB Investor Care

Shares Dilution (1Y)

18.41%

Diluted EPS (TTM)

-0.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	36.9M	66.7M	96.5M	126.3M
2022	110.5M	76.0M	41.6M	7.1M
2021	26.1M	30.0M	155.3M	144.9M
2020	35.4M	28.9M	23.3M	33.2M
2019	31.6M	39.5M	37.5M	34.5M
2018	33.1M	34.7M	20.7M	28.3M
2017	22.1M	22.1M	32.1M	32.1M
2016	5.9M	11.2M	16.5M	21.8M
2015	0	0	0	638.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Seres Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 16, 2024	ege david s.	sold	-5,410	1.08	-5,010	see remarks
Feb 16, 2024	young teresa l.	sold	-3,643	1.08	-3,374	see remarks
Feb 16, 2024	arkowitz david	sold	-4,254	1.08	-3,939	chief financial officer
Feb 16, 2024	von moltke lisa	sold	-4,752	1.08	-4,400	see remarks
Feb 16, 2024	henn matthew r.	sold	-4,503	1.08	-4,170	see remarks
Feb 16, 2024	desrosier thomas	sold	-4,254	1.08	-3,939	chief legal officer and evp
Feb 16, 2024	shaff eric d.	sold	-12,472	1.08	-11,549	ceo and president
Feb 15, 2024	shaff eric d.	acquired	-	-	31,250	ceo and president
Feb 15, 2024	arkowitz david	acquired	-	-	10,625	chief financial officer
Feb 15, 2024	desrosier thomas	acquired	-	-	10,625	chief legal officer and evp

Which funds bought or sold MCRB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Arete Wealth Advisors, LLC	sold off	-100	-34,580	-	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-70.22	-339,490	66,912	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.24	-14,761	7,654	-%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	sold off	-100	-453,893	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-42.36	-36,332	16,995	-%
May 15, 2024	Parallax Volatility Advisers, L.P.	sold off	-100	-60,428	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	16,159	16,159	-%
May 15, 2024	Flagship Pioneering Inc.	unchanged	-	-14,539,300	17,894,900	1.17%
May 15, 2024	Hudson Bay Capital Management LP	added	25.57	-1,849,070	4,199,490	0.02%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	54,650	54,650	-%

Are Funds Buying or Selling MCRB?

Are funds buying MCRB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MCRB

No. of Funds

Unveiling Seres Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	4.5%	6,825,399	SC 13G/A
Feb 12, 2024	janus henderson group plc	0.0%	483	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 29, 2024	blackrock inc.	5.7%	7,339,454	SC 13G
Nov 07, 2023	federated hermes, inc.	4.04%	5,175,805	SC 13G/A
May 10, 2023	federated hermes, inc.	9.00%	11,500,520	SC 13G/A
Apr 06, 2023	blackrock inc.	5.0%	6,249,086	SC 13G/A
Feb 10, 2023	janus henderson group plc	9.0%	11,248,292	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	4.89%	6,092,937	SC 13G/A

Recent SEC filings of Seres Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
Apr 23, 2024	8-K	Current Report

Peers (Alternatives to Seres Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Seres Therapeutics Inc News

Latest updates

Seres Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	64.00	310	126,473	63,724	975	3,444	1,216	4,219	7,221	126,725	9,911	1,070	17,564	1,417	6,045	8,189	7,622	7,031	12,531	7,321
Operating Expenses	0.0%	39,586	39,590	47,723	76,949	70,046	69,282	62,551	64,541	57,244	56,653	58,318	53,405	41,044	35,462	31,412	26,590	27,881	26,814	24,214	23,479	31,874
S&GA Expenses	-100.0%	-	17,234	19,989	28,051	22,470	22,404	18,384	20,335	18,571	20,506	19,563	17,451	11,741	10,595	7,551	6,491	6,138	5,782	5,897	5,574	7,495
R&D Expenses	-19.2%	21,702	26,846	28,253	46,792	43,969	46,220	43,116	43,935	39,649	36,752	39,882	35,954	29,303	24,867	23,861	20,099	21,743	21,032	18,317	17,905	22,887
Interest Expenses	-11.1%	3,580	4,029	4,012	3,187	1,948	1,880	1,727	1,501	912	738	744	732	696	759	730	719	716	-	-	-	-
Net Income	2.7%	-40,133	-41,248	-47,854	46,552	-71,174	-68,796	-60,002	-64,735	-56,624	-50,001	68,218	-48,330	-35,465	-18,252	-30,280	-20,714	-19,881	-18,778	-16,409	-10,759	-24,333
Net Income Margin	27.3%	-0.65*	-0.90*	-1.46*	-2.30*	-7.17*	-35.09*	-5.56*	-1.36*	-0.79*	-0.45*	-0.22*	-4.42*	-	-	-	-	-	-	-	-	-
Free Cashflow	27.0%	-35,298	-48,376	-61,052	64,751	-80,652	-56,353	-60,829	-52,060	-69,395	-53,441	123,650	-42,249	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.8%	341	359	368	406	270	349	312	273	320	355	396	270	306	343	356	101	111	132	124	146	107
Current Assets	-5.8%	165	175	214	251	116	195	248	210	263	304	359	225	252	269	308	73.00	81.00	100	90.00	109	68.00
Cash Equivalents	-6.5%	120	128	170	230	95.00	163	214	135	161	188	227	74.00	67.00	116	207	62.00	55.00	65.00	49.00	102	54.00
Inventory	41.6%	42.00	30.00	19.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-14.9%	19.00	22.00	24.00	24.00	24.00	23.00	19.00	20.00	19.00	18.00	17.00	15.00	14.00	14.00	15.00	16.00	18.00	19.00	21.00	23.00	25.00
Liabilities	-0.6%	401	403	383	384	318	338	244	250	239	223	221	169	162	168	168	166	172	181	156	164	177
Current Liabilities	-0.2%	98.00	99.00	79.00	78.00	64.00	86.00	82.00	89.00	82.00	82.00	95.00	56.00	48.00	46.00	46.00	44.00	44.00	46.00	42.00	43.00	42.00
Shareholder's Equity	-33.2%	-59.74	-44.86	-	23.00	-47.87	11.00	68.00	23.00	81.00	132	176	101	144	175	188	-	-	-	-	-	-
Retained Earnings	-4.1%	-1,018	-978	-936	-889	-935	-864	-795	-735	-670	-614	-564	-632	-584	-548	-530	-500	-479	-459	-440	-424	-413
Additional Paid-In Capital	2.7%	958	933	922	912	888	875	863	759	752	746	740	734	728	723	718	435	418	411	409	406	344
Shares Outstanding	12.1%	151	135	129	128	127	125	102	92.00	92.00	92.00	92.00	92.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	463	-	-	-	240	-	-	-	1,645	-	-	-	220	-	-	-	132	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	25.8%	-35,236	-47,499	-59,255	65,984	-76,584	-52,892	-59,582	-49,897	-66,445	-51,863	127,742	-39,695	-29,496	-17,927	-25,866	-25,566	-24,251	-14,047	-18,292	-11,788	-32,393
Share Based Compensation	27.6%	6,489	5,086	8,673	13,492	6,850	7,291	6,364	6,748	5,079	5,674	5,846	5,078	3,624	2,702	2,249	1,914	1,959	2,145	2,037	2,097	2,065
Cashflow From Investing	92.9%	-62.00	-877	-1,797	10,517	2,739	5,926	40,131	23,399	12,972	13,186	25,112	46,528	-20,738	-75,335	-110,644	17,651	9,437	4,653	-34,524	-341	-306
Cashflow From Financing	191.8%	18,762	6,429	1,443	58,177	5,656	4,597	98,027	130	26,848	-780	609	585	764	1,985	282,300	14,594	4,545	25,110	-118	60,759	480

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MCRB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Collaboration revenue - related party	$ 0	$ (522)
Type of Revenue [Extensible List]	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Total revenue	$ 0	$ (522)
Operating expenses:
Research and development expenses	21,702	43,969
General and administrative expenses	15,466	22,470
Collaboration (profit) loss sharing - related party	2,418	3,607
Total operating expenses	39,586	70,046
Loss from operations	(39,586)	(70,568)
Other income (expense):
Interest income	1,648	1,032
Interest expense	(4,663)	(1,948)
Other income	2,468	310
Total other expense, net	(547)	(606)
Net loss	$ (40,133)	$ (71,174)
Net loss per share attributable to common stockholders, basic	$ (0.27)	$ (0.57)
Net loss per share attributable to common stockholders, diluted	$ (0.27)	$ (0.57)
Weighted-average common shares outstanding, basic	146,101,581	125,862,975
Weighted average common shares outstanding, diluted	146,101,581	125,862,975
Other comprehensive income (loss) :
Unrealized gain (loss) on investments, net of tax of $0	$ 0	$ 12
Currency translation adjustment	0	2
Total other comprehensive income (loss)	0	14
Comprehensive loss	$ (40,133)	$ (71,160)

MCRB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

Current assets:

Cash and cash equivalents

$ 111,184

$ 127,965

Collaboration receivable - related party

7,418

8,674

Inventories

41,973

29,647

Prepaid expenses and other current assets

4,606

9,124

Total current assets

165,181

175,410

Property and equipment, net

19,115

22,457

Operating lease assets

105,669

109,793

Restricted cash

8,430

8,185

Restricted investments

1,401

Other non-current assets

^[1]

41,466

41,354

Total assets

341,262

358,600

Current liabilities:

Accounts payable

5,219

3,641

Accrued expenses and other current liabilities

^[2]

76,317

80,611

Operating lease liabilities

8,833

6,677

Deferred income - related party

8,109

7,730

Total current liabilities

98,478

98,659

Long term portion of note payable, net of discount

102,009

101,544

Operating lease liabilities, net of current portion

103,341

105,715

Deferred revenue - related party

95,364

Warrant liabilities

130

546

Other long-term liabilities

1,678

1,628

Total liabilities

401,000

403,456

Commitments and contingencies (Note 15)

Stockholders' deficit:

Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023

Common stock, $0.001 par value; 240,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 151,442,034 and 135,041,467 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively

151

135

Additional paid-in capital

958,479

933,244

Accumulated other comprehensive loss

Accumulated deficit

(1,018,368)

(978,235)

Total stockholders' deficit

(59,738)

(44,856)

Total liabilities and stockholders' deficit

$ 341,262

$ 358,600

[1]	Includes $38,877 as of March 31, 2024 and December 31, 2023, of milestones related to the construction of the Company's dedicated manufacturing suite at BacThera AG, or Bacthera. Such amounts will form part of the right-of-use asset upon lease commencement.
[2]	Includes related party amounts of $36,211 and $28,053 at March 31, 2024 and December 31, 2023, respectively (see Note 17)

About Seres Therapeutics Inc

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with SociÃƒÂ©tÃƒÂ© des Produits NestlÃƒÂ© S.A. (NestlÃƒÂ©) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Eric D. Shaff M.B.A.
WEBSITE	serestherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	431

Seres Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Seres Therapeutics Inc? What does MCRB stand for in stocks?

MCRB is the stock ticker symbol of Seres Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seres Therapeutics Inc (MCRB)?

As of Fri May 17 2024, market cap of Seres Therapeutics Inc is 139.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MCRB stock?

You can check MCRB's fair value in chart for subscribers.

What is the fair value of MCRB stock?

You can check MCRB's fair value in chart for subscribers. The fair value of Seres Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Seres Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MCRB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Seres Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MCRB is over valued or under valued. Whether Seres Therapeutics Inc is cheap or expensive depends on the assumptions which impact Seres Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MCRB.

What is Seres Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MCRB's PE ratio (Price to Earnings) is -1.69 and Price to Sales (PS) ratio is 1.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MCRB PE ratio will change depending on the future growth rate expectations of investors.